- Conditions
- Neuroendocrine Tumors
- Interventions
- fosbretabulin tromethamine
- Drug
- Lead sponsor
- Mateon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Stanford, California • Lexington, Kentucky • The Bronx, New York + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 929
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
- Interventions
- SBP-101
- Drug
- Lead sponsor
- Panbela Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- PEGPH20, Oxaliplatin, Leucovorin, Irinotecan, 5-fluorouracil
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 154
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Auburn, California + 112 more
- Conditions
- Colorectal Adenocarcinoma, Cholangiocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma
- Interventions
- ceritinib
- Drug
- Lead sponsor
- Criterium, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 3 more
- Conditions
- Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma
- Interventions
- MRTX1133
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Lady Lake, Florida + 9 more
- Conditions
- Cancer, Pancreas
- Interventions
- Radiation Therapy, Capecitabine, Oxaliplatin
- Radiation · Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Locally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Gemcitabine, Nab-paclitaxel, Telotristat Ethyl
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma
- Interventions
- Aglatimagene besadenovec, Chemoradiation, Stereotactic body radiation therapy, Surgery
- Biological · Radiation · Procedure
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 2
- States / cities
- Fort Myers, Florida • Columbus, Ohio
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
- Interventions
- siG12D-LODER, Gemcitabine+nab-Paclitaxel, Folfirinox
- Drug
- Lead sponsor
- Silenseed Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Hackensack, New Jersey • New York, New York • Houston, Texas
- Conditions
- Adenocarcinoma of the Pancreas
- Interventions
- Paricalcitol, Abraxane, Gemcitabine
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
- Interventions
- DSB2455
- Drug
- Lead sponsor
- Duke Street Bio Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Sacramento, California • New Haven, Connecticut • New York, New York + 1 more
- Conditions
- Pancreatic Cancer
- Interventions
- Synthetic Human Secretin, Secretin-Enhanced Magnetic Resonance Cholangiopancreatography, Secretin-Enhanced Endoscopic Ultrasound
- Drug · Procedure
- Lead sponsor
- Elizabeth Hecht
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- PCX-12
- Drug
- Lead sponsor
- Haoming (Carl) Qiu
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- IPMN, Pancreatic, Pancreas Cancer, Pancreatic Cyst
- Interventions
- LINFU®
- Diagnostic Test
- Lead sponsor
- Adenocyte, LLC
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2034
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, bevacizumab, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Sarcoma, Mesothelioma, Neuroendocrine Tumors, Squamous Cell Cancer, Merkel Cell Carcinoma, Mismatch Repair Deficiency, Microsatellite Instability
- Interventions
- Tumor Infiltrating Lymphocytes (TIL), Fludarabine + Cyclophosphamide combination
- Biological · Drug
- Lead sponsor
- Udai Kammula
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2038
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms, Endocrine Gland Neoplasms, Pancreatic Diseases, Digestive System Diseases, Endocrine System Diseases, Gemcitabine, Antimetabolites, Antineoplastic
- Interventions
- nab-Paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 866 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 107
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 51 more
- Conditions
- Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Interventions
- PF-08046037, sasanlimab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 14
- States / cities
- Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more
- Conditions
- Pancreatic Cancer
- Interventions
- panitumumab, erlotinib hydrochloride, gemcitabine hydrochloride
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 262
- States / cities
- Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 163 more
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
- Interventions
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Biological · Diagnostic Test
- Lead sponsor
- A2 Biotherapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 12
- States / cities
- Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Pancreatic Cancer
- Interventions
- Capecitabine, Docetaxel
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Miami, Florida • Miami Beach, Florida
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Tumor markers
- Other
- Lead sponsor
- Olympus Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
- Interventions
- IPN01194
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California • New Haven, Connecticut + 2 more
- Conditions
- Pancreatic Cancer
- Interventions
- Gemcitabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas